Intuitive Surgical (NASDAQ:ISRG) was reiterated as Outperform but price target raised to $785 from $755 by brokers at Wedbush on Wednesday.
“With a solid 3Q driven by system placements and procedure growth, we are increasingly confident that ISRG can maintain its robust growth prospects. ISRG should benefit from the continued adoption of da Vinci surgery across a growing number of surgical specialties and geographies,” Wedbush said in a note.
Although the shares ended 5.6% lower, after hours they gained 1% to $688.50.
Meanwhile, Clearside Biomedical (NASDAQ:CLSD) shares slid 7.6% to $20.19 after Wedbush reiterated its Outperform recommendation and maintained target at $28.
“Clearside's suprachoroidal space (SCS) microinjector drug delivery is creating a superior clinical profile for corticosteroid therapy into the eye in our view with improved safety and efficacy compared to standard IVT delivery,” the broker said.
Clearly, not enough to save the stock from a sharp decline this session.
St. Jude Medical, Inc. (NYSE:STJ) was rated Neutral and target maintained at $84 by Wedbush on Wednesday.
“We continue to expect the acquisition of STJ by Abbott Laboratories (ABT, not rated) to close by year-end 2016; both management teams expressed confidence in this timeline despite other distractions (e.g., cybersecurity and product recall worries),” Wedbush said.
St Jude’s shares ended down 0.9% at $78.70.